Dynavax Technologies Corporation (NASDAQ:DVAX) announced its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.15, Bloomberg Earnings reports. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. The company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.28 million. During the same quarter in the previous year, the business earned ($0.90) EPS. Dynavax Technologies Corporation’s revenue was down 68.8% compared to the same quarter last year.

Dynavax Technologies Corporation (NASDAQ:DVAX) traded up $0.60 during trading on Friday, reaching $21.60. The company’s stock had a trading volume of 1,396,470 shares, compared to its average volume of 1,408,759.

TRADEMARK VIOLATION NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/11/04/dynavax-technologies-corporation-dvax-announces-earnings-results-beats-estimates-by-0-15-eps.html.

A number of research analysts recently issued reports on the company. Cowen and Company restated a “buy” rating and set a $30.00 price target on shares of Dynavax Technologies Corporation in a report on Friday. Royal Bank Of Canada restated an “outperform” rating and set a $28.00 price target (up previously from $26.00) on shares of Dynavax Technologies Corporation in a report on Monday, September 25th. Cantor Fitzgerald started coverage on Dynavax Technologies Corporation in a report on Friday, September 15th. They set an “overweight” rating and a $24.00 price target on the stock. ValuEngine raised Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, September 7th. Finally, William Blair reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Dynavax Technologies Corporation in a research report on Wednesday, August 9th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Dynavax Technologies Corporation currently has a consensus rating of “Buy” and an average target price of $25.00.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Earnings History for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.